Updated Guidelines for Papanicolaou Tests, Colposcopy, and Human Papillomavirus Testing in Adolescents

Journal of Adolescent Health

Volumn 43, Issue 4 SUPPL., 2008, Pages

  Widdice, Lea E ^a   Moscicki, Anna Barbara ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adolescent; Cervical intraepithelial neoplasia; Evidence based medicine; Guidelines; HPV; Screening; Uterine cervical dysplasia; Uterine cervical neoplasm

Indexed keywords

PROTEIN E6; PROTEIN E7;

CANCER SCREENING; COLPOSCOPY; CYTOLOGY; EVIDENCE BASED MEDICINE; HEALTH CARE; HEALTH CARE SYSTEM; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; PAPANICOLAOU TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; UTERINE CERVIX TUMOR; VERRUCA VULGARIS; VIROLOGY; VIRUS INFECTION; VIRUS TRANSMISSION; WART VIRUS;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 52049095506     PISSN: 1054139X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jadohealth.2008.04.007     Document Type: Review

References (47)

1. Ferlay J., et al. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5 Version 2.0. (2004), IARC Press, Lyon, France
2. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 110 (2006) 525-541
3. Muñoz N., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
4. Trottier H., and Franco E.L. The epidemiology of genital human papillomavirus infection. Vaccine 24 Suppl 1 (2006) S1-S15
5. Woodman C.B., et al. Natural history of cervical human papillomavirus infection in young women: A longitudinal cohort study. Lancet 357 (2001) 1831-1836
6. Winer R.L., et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 191 (2005) 731-738
7. Schlecht N.F., et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 95 (2003) 1336-1343
8. Muñoz N., et al. Chapter 1:HPV in the etiology of human cancer. Vaccine 24S3 (2006) S1-S10
9. Solomon D., et al. The 2001 Bethesda System: Terminology for reporting results of cervical cytology. JAMA 287 (2002) 2114-2119
10. Moscicki A.B., et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 364 (2004) 1678-1683
11. Syrjanen K., et al. Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System. Obstet Gynecol 79 (1992) 675-682
12. Myers E.R., et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 151 (2000) 1158-1171
13. Carreon J.D., et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: Results from a histological review of population-based cervical samples. Int J Gynecol Pathol 26 (2007) 441-446
14. Winer R.L., et al. Genital human papillomavirus infection:incidence and risk factors in a cohort of female university students. Am J Epidemiol 157 (2003) 218-226
15. Palefsky J.M., et al. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis 183 (2001) 383-391
16. Marrazzo J.M., et al. Papanicolaou test screening and prevalence of genital human papillomavirus among women who have sex with women. Am J Public Health 91 (2001) 947-952
17. Burchell A.N., et al. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine 24 Suppl 3 (2006) S52-S61
18. Moscicki A.B., et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 285 (2001) 2995-3002
19. Ho G.Y., et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338 (1998) 423-428
20. Dunne E.F., et al. Prevalence of HPV infection among females in the United States. JAMA 297 (2007) 813-819
21. de Sanjose S., et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-analysis. Lancet Infect Dis 7 (2007) 453-459
22. Clifford G.M., et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys:a pooled analysis. Lancet 366 (2005) 991-998
23. Clifford G., et al. HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24 Suppl 3 (2006) S26-S34
24. Evander M., et al. Human papillomavirus infection is transient in young women: A population-based cohort study. J Infect Dis 171 (1995) 1026-1030
25. Moscicki A.B., et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 132 (1998) 277-284
26. Mount S.L., and Papillo J.L. A study of 10,296 pediatric and adolescent Papanicolaou smear diagnoses in northern New England. Pediatrics 103 (1999) 539-545
27. Bjorge T., et al. Cervical mass screening in Norway-510,000 smears a year. Cancer Detect Prev 18 (1994) 463-470
28. Wright Jr. T.C., et al. 2006 Consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis 11 (2007) 223-239
29. Moscicki A.B., et al. Years sexually active and oral contraceptives are a risk for CIN 3 in adolescents and young women. 23rd International Papillomavirus Conference and Clinical workshop 2006 Book of Abstracts. September (2006), The Institute of Hematology and Blood Transfusion, Praha, Czech Republic 18
30. Insinga R.P., Glass A.G., and Rush B.B. Diagnoses and outcomes in cervical cancer screening: A population-based study. Am J Obstet Gynecol 191 (2004) 105-113
31. Schiffman M., and Kjaer S.K. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 31 (2003) 14-19
32. Ries L., et al. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute (2007). http://seer.cancer.gov/csr/1975_2004/ Last accessed June 11, 2008
33. Kjaer S.K., et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: Population based prospective follow up study. Br Med J 325 (2002) 572
34. Castellsague X., Muñoz N., et al. Cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 31 (2003) 20-28
35. Moscicki A.B., et al. The significance of squamous metaplasia in the development of low grade squamous intraepithelial lesions in young women. Cancer 85 (1999) 1139-1144
36. Winer R.L., et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 354 (2006) 2645-2654
37. Garnett G.P., et al. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 24 Suppl 3 (2006) S178-S186
38. Saslow D., et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. J Low Genit Tract Dis 7 (2003) 67-86
39. Saslow D., et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 52 (2002) 342-362
40. ACOG practice bulletin. Cervical cytology screening. Int J Gynaecol Obstet 83 (2003) 237-247
41. Mayrand M.H., et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357 (2007) 1579-1588
42. Naucler P., et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 357 (2007) 1589-1597
43. Runowicz C.D. Molecular screening for cervical cancer-time to give up Pap tests?. N Engl J Med 357 (2007) 1650-1653
44. Screening for cervical cancer, [topic page]. January 2003. U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/uspstf/uspscerv.htm. Last accessed June 11, 2008.
45. Wright Jr. T.C., et al. 2006 Consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 11 (2007) 201-222
46. Wright Jr. T.C., et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 197 (2007) 346-355
47. Wright Jr. T.C., et al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 197 (2007) 340-345